

- Nov 8
Check out the latest publication from the Cameron Lab
A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and...
The Cameron Lab has over two decades of expertise integrating experimental and computational approaches to better understand complex biological systems.
We offer state-of-the-art single cell, spatial, and multi-omic gene expression analysis. We specialize in simplifying the complexity of OMICs data analysis and interpretation, utilizing the most innovative technologies available.
Single cell and spatial sequencing
10X Genomics Chromium X (2022) controller
10X Visium Spatial Seq
NanoString GeoMx spatial sequencer (2022)
QC and Quantification
Nexcellom K2 Cell Counter
BSL2+ certified state-of-the-art facility
We have close partnerships with
UH Research Pathology Core
Capadona Lab at VA
Cleveland Clinic, University Hospitals and Metro Health
The AFGC serves as the backing core for
Nanostring GeoMx
10X Visium
Combine histology and RNA/protein analysis to capture the positional context of gene expression within intact tissue
Data QC and processing
Expert OMICS data analysis and interpretation
Extract meaningful information from large, complex data sets and communicate new insights with high-quality visualization and reports
Combine various high-throughput techniques, such as simultaneous detection of mRNA and chromatin from the same cell, to study biological systems at multiple levels of organization
10X Single Cell RNA-seq
10X Single Cell ATAC-seq + Gene expression
Low input/bulk RNA-seq
Team of skilled scientists
Specialized expertise in systems biology
Leverage the full potential of the latest OMICs technology to address your research questions with guidance from experimental design to analysis and interpretation
Dr. Mark Cameron applies genomic technologies and bioinformatic methods to identify biomarkers (immune correlates) of infectious diseases, such as HIV, and chronic inflammatory conditions, such as psoriasis. He and his team have broad computational expertise in analyzing across data types and studies, and focus their work on targets or diagnostics that can be used in specific immunotherapy or vaccine design. Dr. Cameron also directs the genomics activities of several large cores or consortia, including the Case Western Reserve University Applied Functional Genomics Core, the Miami Center for AIDS Research (Inter-CFAR) Bioinformatics Core, the Case Western Reserve University CFAR Systems Biology Core, and the international Early Treated Perinatally Infected individuals: Improving Children’s Lives with an HIV Vaccine (EPIICAL). These collaborative cores allow Dr. Cameron to apply his systems approach and data from gene sequence, to gene transcription, to protein, cellular and antibody function, to find out what goes right or wrong in the immune systems of patients who respond variably to various diseases or treatments.
Dr. Cheryl Cameron completed her Ph.D. in virology in the laboratory of Dr. Grant McFadden at Western University, computationally identifying novel viral immunomodulatory proteins such as the CD47 and CD200 homologues encoded by myxomavirus, a close relative of smallpox. She went on to pursue a post-doctoral fellowship in viral immunopathogenesis at the University of Toronto, applying transcriptomic analyses to dissect the host response to pathogenic respiratory viruses such as SARS-CoV-1 and avian influenza virus to identify key determinants of severe outcome. Dr. Cameron has continued to study the complex interplay between the host and virus, using objective computational approaches to identify mechanisms of disease pathogenesis and novel targets for immunomodulatory therapeutic interventions to improve the outcome in infected individuals. She went on to study chronic viral infection in people living with HIV, and has discovered that many of the host immune pathways that are highly dysregulated in viral infection are similarly dysregulated in cancer and in other diseases characterized by chronic inflammation, such as cardiovascular disease, heart failure and psoriasis. Importantly, many of these pathways are metabolic in nature and are impacted by diet, nutrition, and drug abuse. Most recently, Dr. Cameron has revived her SARS coronavirus research program and is actively studying the host immune response to SARS-CoV-2 in an effort to identify predictive biomarkers of disease severity as well as potential therapeutic targets to reverse the immune pathology seen in COVID-19. Dr. Cameron was excited to join the Department of Nutrition in 2019 as a translational researcher, and is happy to discuss opportunities for undergraduate and graduate students to participate in her research program, either by assisting in the analysis of big data, or by performing wet lab research.